Chiasma Inc (CHMA.OQ)
CHMA.OQ on NASDAQ Stock Exchange Global Select Market
3.74USD
19 Oct 2018
3.74USD
19 Oct 2018
Change (% chg)
$0.02 (+0.54%)
$0.02 (+0.54%)
Prev Close
$3.72
$3.72
Open
$3.71
$3.71
Day's High
$3.76
$3.76
Day's Low
$3.71
$3.71
Volume
4,546
4,546
Avg. Vol
15,885
15,885
52-wk High
$3.80
$3.80
52-wk Low
$1.20
$1.20
About
Chiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial... (more)
No analyst recommendations are available for .
Overall
| Beta: | -- |
| Market Cap(Mil.): | $70.64 |
| Shares Outstanding(Mil.): | 24.36 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| CHMA.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 30.90 | 33.64 |
| EPS (TTM): | -1.28 | -- | -- |
| ROI: | -34.47 | 14.75 | 14.27 |
| ROE: | -35.41 | 16.24 | 15.99 |
BRIEF-Chiasma Announces FDA Agreement To Redefine Certain Secondary Endpoints In Phase 3 Clinical Trial
* CHIASMA ANNOUNCES FDA AGREEMENT TO REDEFINE CERTAIN SECONDARY ENDPOINTS IN CHIASMA OPTIMAL PHASE 3 CLINICAL TRIAL
Earnings vs. 
Estimates